CONFERENCE PROGRAM

Sunday, 2 October 2016			
08:00-19:00	Registration		
9:30-9:55	**Coffee Social *(Foyer of Grand Ballroom)*** **Sponsored by EpiVax, Inc.**		
9:55-10:00	**Opening Remarks *(Grand Ballroom)*** **ISV Congress Co-chairs: Margaret Liu, David Weiner, Anne De Groot**		
10:00-12:15	**Plenary Session One: Vaccine Challenges *(Grand Ballroom)*** **Session Chairs: Shan Lu and Margaret Liu**		
10:00-10:30	**[PL1.1] The Ebola Disaster and How to Prevent it from Happening Again** Stanley Plotkin, *VaxConsult*		
10:30-11:00	**[PL1.2] Development of V920, Live, Attenuated Recombinant Vesicular Stomatitis Vaccine Against Ebola Zaire (rVSV-ZEBOV)** Tom Monath, *New Link Genetics*		
11:00-11:30	**[PL1.3] Chimpanzee Adenoviral Vectors as Vaccines: from Alphaviruses to Zika** Adrian Hill, *Oxford University*		
11:30-12:15	**[PL1.4] Panel: Challenges of Making Emerging Diseases Vaccines** **Session Chair:** Stanly Plotkin, *VaxConsult* **Panelists:** Phil Krause**,** *Food and Drug Administration,* Rip Ballou, *GSK* Adrian Hill, *Oxford University,* Tom Monath*, New Link Genetics*		
12:15-13:30	**Lunch *(Harbor View Ballroom and Commonwealth Ballroom)*** **Sponsored by Ichor Medical System, Inc.**		
13:30-15:30	**Concurrent Session 1:** **Mechanisms of Immune Efficacy** **Session Chairs: Nik Petrovksy and Peter Nara**	**Concurrent Session 2:** **DNA Vaccines** **Session Chair: David Weiner** **Sponsored by:** **Inovio Pharmaceuticals** **Sponsored by:** **Eurogentec**	**Concurrent Session 3:** **Zoonoses and Animal Models for Evaluating Vaccine Protection** **Session Chairs: Cyril Gay and Bin Wang**
13:30-14:00	**Towards a Universal Influenza Virus Vaccine** Adolfo Garcia-Sastre, *Icahn School of Medicine at Mount Sinai*	**[O2.1] Of Road Maps & Time Lines: Vaccines for EIDs** Joel Maslow*, GeneOne*	**[O3.1] Immunotherapeutic Approaches for Alzheimer and Prion Diseases** Thomas Wisniewski, *NYU School of Medicine*
14:00-14:15	**[O1.2] The generation of an immunogenic second-generation conserved segment HCV T-cell vaccine to target multiple HCV genotypes**. Timothy Donnison, *Oxford Univ.*	**[O2.2] Advancing the mRNA therapeutics platform for vaccines** Hari Pujar*, Moderna Therapeutic*	**[O3.2] Prevention of emerging zoonoses in Central Africa: an overview from a veterinary perspective.** Emmanuel Assana, *University of Ngaoundéré*
14:15-14:30	**[O1.3] HSV-2 vaccine virus deleted in glycoprotein D (ΔgD-2) elicits high-titer IgG2 antibodies that activate the FcR and protect mice and guinea pigs from skin or vaginal challenge with clinical isolates of HSV-1 and HSV-2, and prevent the establishment of latency.** William R. Jacobs, Jr., *Howard Hughes Medical Institute, Albert Einstein College of Medicine*		**[03.3] The enhanced immune responses of pig to PCV-2 vaccine by inoculation with chitosan nanoparticles of recombinant pig interleukin-23 gene.** Yongle Xiao, *Sichuan University*
14:30-14:45	**[O1.4] Immunogenicity and Efficacy of a Trivalent HSV-2 gC2/gD2/gE2 Subunit Antigen Vaccine in Rhesus Macaques and Guinea Pigs** Harvey Friedman, *UPenn*	**14:30-15:00** **[02.3] BEAT-HIV Collaboratory: Path to a Cure**. Luis Montaner, *Wistar Institute*	[**O3.4] Broadly Protective Influenza Vaccines: Protection against mismatch – bettering standard of care.** Harold Kleanthous, *Sanofi-Pasteur*

14:45-15:00	**[01.5] Decoding Immune Evading Mechanisms of pathogens: reordering of immunodominance for new and improved vaccines** Peter Nara, *Biological Mimetics*	**14:30-15:00 [02.3] BEAT-HIV Collaboratory: Path to a Cure**. Luis Montaner, *Wistar Institute (Continued)*	**[O3.5] Pathologic and Immunologic characteristics of Coxsackievirus A16 infection in rhesus macaques.** Ying Zhang, *Chinese Academy of Medical Sciences*
15:00-15:15	**[O1.6] LAMP-based DNA vaccines suppress IgE production and intestinal anaphylaxis in a murine model of Peanut-induced Food Allergy** Franco Pissani, *Immunomics Therapeutic,*	**[O2.4] Two doses of a DNA Vaccine Expressing the Glycoprotein Precursor Gene of Lassa Virus Fully Protect Nonhuman Primates from Lassa Fever when Delivered by Dermal Electroporation** Kathleen Cashman, *USAMRIID*	**[O3.6] An optimized synthetic DNA vaccine targeting liver stage exported proteins provides sterilizing protection from P. yoelii sporozoite challenge.** Emma Reuschel, *Wistar Institute*
15:15-15:30	**[O1.7] Microneedle-based cutaneous immunotherapy for allergy treatment** Akhilesh Kumar Shakya, *Texas Tech Univ.*	**[O2.5] Comparative evaluation of electroporation mediated intradermal or intramuscular administration of DNA vaccines against the Venezuelan, eastern, and western encephalitic alphaviruses.** Drew Hannaman, *Ichor Med. Sys.*	**[O3.7] Identification and validation of immunodominant antigens as protective prophylactic against Shigella**. Bhrugu Yagnik, *Sardar Patel University*
15:30-16:00	**Coffee Break *(Foyer of Grand Ballroom)***		**Sponsored by Pfizer Inc**
16:00-18:00	**Plenary Session 2: Insights into the Immunology of Vaccines and Immunotherapy** **Session Chairs: Adolfo Garcia-Sastre and Anna-Lise Williamson**		
16:00-16:30	**[O9.9] Upper Respiratory Tract (URT) Administration of a Replication-Competent Ad4-H5-Vtn Vaccine Induces Durable Neutralizing Antibody Responses in Humans.** Mark Connors, *LIR, NIAID*		
16:30-17:00	**[PL2.2] A Replication Defective Human Cytomegalovirus Vaccine for Prevention of Congenital Infection** Tong-Ming Fu, *Merck*		
17:00-17:15	**[PL2.3] Adjuvants play a critical role in universal influenza vaccine design** Nik Petrovsky, *Flinders University*		
17:15-17:30	**[PL2.4] Side-Stepping Regulatory T Cell Induction to Build Better Vaccines** Anne De Groot, *EpiVax, Univ. of Rhode Island*		
17:30-17:45	**[PL2.5] An Optimized, Synthetic DNA Vaccine Encoding the Toxin A/Toxin B RBDs of Clostridium difficile Induces Protective Antibody Responses.** Michele Kutzler, *Drexel Univ.*		
17:45-18:00	**[PL2.6] A subunit protein based therapeutic vaccine design to treat Genital Herpes disease and subclinical infection in a pre-clinical model.** Sita Awasthi, *Univ. Penn.*		
18:15-20:00	**Poster Session and Reception *(Palm Garden)***		
	Monday, 3 October 2016		
08:00-18:00	Registration		
08:00-10:00	**Plenary Session 3: Global Health Issues and Vaccine Approcahes** **Session Chairs: William Jacobs and Yvonne Maldonado**		
08:00-0830	**[PL3.1] Keynote speech, Biosecurity and winning the war against future epidemics** Victor Dzau, *National Academy of Medicine, US National Academy of Sciences*		
08:30-09:00	**[PL3.2] AIDS, Avian flu, SARS, MERS, Ebola, Zika …what next?** Ab Osterhaus, *Univ. Veterinary Medicine Hannover*		
09:00-09:30	**[PL3.3] The Power of Cryptic Epitopes in Designing Vaccines** Michael Good, *Griffith Univ.*		
09:30-09:45	**[PL3.4] Clinical Development of Novel Conserved Element HIV pDNA Vaccine Able to Maximize Breadth and Magnitude of Immune Responses.** Barbara Felber, *NCI*		
09:45-10:00	**[PL3.5] Unitizing MVA-VLP platform for development of single dose vaccines: Tetravalent vaccine against hemorrhagic fever and Zika viruses.** Farshad Guirakhoo, *GeoVax*		

10:00-10:30	**Coffee Break *(Foyer of Grand Ballroom)*** **Sponsored By Nature Technology Corporation**		
10:30-12:45	**Concurrent Session 4: Institut Pasteur Special Session Session Chairs: Christiane Gerke and Shan Lu**	**Concurrent Session 5: Vaccines and Biologicals: Production and Efficacy Session Chairs: Phil Krause and Britta Wahren**	**Concurrent Session 6: JSV/KVS: Adjuvant and Immunomodularity Principles for Mucosal vs. Systemic Immunity Session Chairs: Hiroshi Kiyono and Baik Lin Seong**
10:30-11:00	**[O4.1] Challenges and opportunities of yellow fever vaccination in Africa: Implications and lessons for Global Health.** Amadou Alpha Sall, *Institut Pasteur, Dakar, Senegal*	**[O5.1] Plant Production of Vaccines** Ed Rybicki, *Univ. of Cape Town*	**[O6.1] Herpes Zoster Subunit Vaccine – Overcoming Immunosenescence in the Elderly.** Tom Heineman, *GSK*
11:00-11:30	**[04.5] Synthetic carbohydrate-based conjugates as vaccines: a promising concept illustrated for *Shigella*** Laurence Mulard, *Institut Pasteur, Paris, France*	**[O5.2] Ebola Zaire vaccine manufacturing using Janssen's Adenovirus platform in response to global public health emergency and beyond.** Joanke Graveland-Bikker, *Janssen*	**[O6.2] Flagellin as a versatile adjuvant for mucosal vaccines.** Joon Haeng Rhee, *Chonnam Nat'l. Univ.*
		[O5.3] Expanding Global Vaccine Availability Through Supported Technology Transfer to DCVM-The IVI Experience Julia Lynch, *IVI*	
11:30-12:00	**[O4.3] Vaccinology at Institut Pasteur** Christiane Gerke, *Institut Pasteur, Paris, France*	**[O5.4] Boosting vaccine development for infectious diseases of low and middle income countries.** Allan Saul, *GSK Vaccines Inst.*	**[O6.3] A system vaccinological approach to vaccine and adjuvant safety: establishment of a novel safety evaluating system.** Eita Sasaki, *National Inst. of Infectious Disease*
		[O5.5] ChimeriVax-based Zika vaccine, a live-attenuated approach. Fernando Diaz, *Sanofi-Pasteur*	**[O6.4] Adjuvant Formulations and Delivery Platforms Influence the Antibody Responses to Trimeric gp145 and gp120 HIV-1 Envelope Proteins.** Mangala Rao, *Walter Reed Army Inst.*
12:00-12:15	**[O4.4] Towards a broadly protective polyvalent virus-like particle vaccine against hand, foot and mouth disease**. Xia Jin, *Institut Pasteur Shanghai, Shanghai, China*	**[O5.6] DNA-delivery of monospecific and bispecific monoclonal antibodies targeting Pseudomonas aeruginosa expresses functional antibodies that protect mice in a lethal model of pneumonia.** Ami Patel, *Wistar Institute*	**[O6.5] Poly-IC synergizes with OX40 to enhance Ag-specific CD4 T cell response.** Paurvi Shinde, *U. Conn*

12:15-12:30	**[O4.2], Development of live measles vaccine vector for new emerging pathogens.** Frédéric Tangy, *Institut Pasteur, Paris, France* *Presented by Christiane Gerke*	**[O5.7] Electroporation-Mediated DNA Administration as an Antibody Delivery Platform for Passive Immunoprophylaxis**. Claire Evans, *Ichor Medical Systems*	**[O6.6] Amyloid-inspired Synthetic Peptide Hydrogels as Vaccine Adjuvants.** Jai Rudra, *U. Texas Med. Branch*
12:30-12:45	**[04.6] A promising vaccine against bubonic and pneumonic plague** Anne Derbise, *Institut Pasteur, Paris, France*	**[O5.8] Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice.** Yu Zhou, *Shanghai Univ.*	**[O6.7] Sulfated Archaeal Glycolipids as a Safe & Effective Vaccine Adjuvant for Induction of Cell-mediated Immunity.** Michael McCluskie, *Nat'l. Res. Council Canada*
12:45-13:45	**Lunch *(Harbor View Ballroom and Commonwealth Ballroom)*** **Sponsored By VGXI**		
13:15-14:15	**Poster Session 2 *(Palm Garden)***		
14:15-15:00	**ISV Annual Meeting *(Grand Ballroom)***		
15:00-15:30	**Coffee Break *(Foyer of Grand Ballroom)*** **Sponsored By Eurogentec**		
15:30-17:45	**Pleanary Session 4: Immunization of Individuals in Special Physiological Circumstances** **Session Chairs: Sam Katz and Jeffrey Ulmer**		
15:30-16:00	**[PL4.1] Issues for the Endgame of Polio Eradication and the limitations of the Immunogenicity of OPV** Yvonne Maldonado, *Stanford Univ.*		
16:00-16:30	**[PL4.2] Maternal Immunization** Flor Munoz, *Baylor College of Medicine*		
16:30-17:00	**[PL4.3] Group B *streptococcus* vaccination in pregnant women with or without HIV in Africa** Clare Cutland, *Univ. of the Witwatersrand*		
17:00-17:15	**[PL4.4] Replication-defective lymphocytic choriomeningitis virus vectors expressing HPV16 antigens for therapeutic vaccination and cancer immunotherapy.** Anders Lilja, *Hookipa Biotech*		
17:15-17:30	**[PL4.5] Regression of Advanced Cervical Dysplasia and Elimination of HPV16/18 Infection by VGX-3100 is Statistically Associated with the Presence of Highly Active Peripheral Lytic CD8+ T cells and Cervical Immune Infiltration.** Kimberly Kraynyak, *Inovio*		
17:30-17:45	**[PL4.6] A Novel Heroin Conjugate Vaccine Abrogates Nociceptive and Behavioral Effects of Heroin through the Induction of High Titer and High Affinity Antibodies to Heroin and Its Degradation Products.** Gary Matyas, *Walter Reed Army Inst. of Research*		
19:00-22:00	**ISV Congress Dinner *(New England Aquarium – tickets required)***		
	Tuesday, 4 October 2016		
08:00-14:00	Registration		
08:00-10:00	**Plenary Session 5: Insights into Vaccine Targets and Effective Immune Responses** **Session Chairs: Flor Munoz and Marie-Paule Kieny**		
08:00-08:30	**[PL5.1] Factors Affecting Vaccine Investment by Companies** Luis Jodar, *Pfizer*		
08:30-09:00	**[PL5.2] Novel Biomarkers for antibody-directed effector function predicting vaccine efficacy.** Galit Alter, *Harvard Medical School/MIT*		
09:00-09:15	**[PL5.3] Different Strains of Recombinant *Mycobacterium bovis* Bacillus Calmette–Guérin (BCG) Expressing HIV Gag Prime Different Types of Immune Responses When Boosted with SAAVI MVA-C.** Anna-Lise Williamson, *U. Cape Town*		
09:15-09:30	**[PL5.4] Env-specific Rabbit Antibody-Mediated ADCC Activities vis Human Fc-Receptor**. Shixia Wang, *UMMS*		
09:30-09:45	**[PL5.5] Elimination of HIV from infected cells by IgG-conjugated enfuvirtide.** Britta Wahren, *Karolinska Inst.*		
09:45-10:00	**[PL5.6] Conformation of a Protein in Virus-like Particles Impacts their Efficacy as Vaccines.** Trudy Morrison, *UMMS*		
10:00-1030	**Coffee Break *(Foyer of Grand Ballroom)*** **Sponsored By Regeneron**		

10:30-12:45	Concurrent Session 7: New and Transformed Vaccine Technologies (KVS/JSV session) Session Chairs: Joon Rhee and Julia Lynch	Concurrent Session 8 : Emerging and Re-emerging Diseases; VaxRen Session Session Chairs: Anne De Groot and Connie Schmaljohn	Concurrent Session 9: Vaccines Against Respiratory Pathogens Session Chairs: Ted Ross and Linda Klavinskis
10:30-11:00	**[O7.1} Can serum vibriocidal antibodies mediate bactericidal activity against *Vibrio cholerae* O1 in the small intestine of persons recovered from wild type cholera and in recipients of live oral vaccine?** Myron Levine, *Center for Vaccine Devlopement, Univ. of Maryland*	**[O8.1] Q Fever; Immune Profiling of Coxiella burnetii Vaccination and Infection by Mass Cytometry** Mark Pozansky, *Mass.General Hospital,* Patrick Reeves, *Mass General Hospital*	**[O9.1] A New Genome-Wide Antigen Discovery Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis (IVE-TB) Antigens Inducing Human T Cell Responses with Classical and Unconventional Cytokine Secretion Profiles.** Mariateresa Coppola, *Leiden Univ.*
			[O9.2] Both young and aged effector CD4 T cells that recognize cognate Ag at the "memory checkpoint" differentiate to Tfh and memory cells and promote B cell memory in a vaccine model. Jingya Xia, *UMMS*
11:00-11:15	**[O7.2] A novel RSV vaccine elicits humoral and Treg-cell responses against RSV infection and suppresses vaccine enhanced disease (VED).** Bin Wang, *Fudan Univ.*	**[O8.2] Ebola Challenge Study in Non-Human Primates: Role in Supporting the Development of rVSV-EBOV Vaccine.** Amy Shurtleff, *USAMRIID*	**[O9.3] Characterization of Influenza Elicited Humoral Immunity in the domestic Ferret.** Greg Kirchenbaum, *U. Georgia*
11:05-11:30	**[O7.3] Green tea catechin-inactivated viral vaccine.** Baik Lin Seong, *Yonsei Univ.*	**[O8.3] A Phase 1 Study of a DNA Vaccine for Venezuelan Equine Encephalitis Delivered by Intramuscular or Intradermal Electroporation**. Lesley Dupuy, *USAMRIID*	**[O9.4] Development of a safe, tolerable and efficacious gene-based immunoprophylaxis delivery strategy to protect against RSV.** Trevor Smith, *Inovio*
11:30-11:45	**[O7.4] Preclinical evaluation of hemagglutinin stalk-based candidate universal influenza vaccines in ferrets.** Randy Albrecht, *Mount Sinai Med. School*	**[O8.4] Confirmation of a lethal mouse model for Zika virus infection and development of a novel DNA vaccine that is fully protective against lethal infection in vivo.** Trina Racine, *Canadian Science Centre for Human and Animal Health*	**[O9.5] Formulation of the RSV fusion protein with a novel combination adjuvant mediates the induction of long-term immune memory and disease protection**. Sylvia Van Den Hurk, *VIDO-Intervac*
11:45-12:00	**[O7.5] An alternative platform for the development of live attenuated influenza virus vaccines.** Jefferson Santos, *U. Georgia*	**[O8.5] Identification of dengue-specific and cross-reactive B cells using labeled viruses following natural infection and vaccination.** Anuja Mathew, *U. Rhode Island*	**[O9.6] Broad Cross-Protective Anti-Hemagglutination Responses Elicited by Influenza Micro-Consensus DNA Vaccine.** Jian Yan, *Inovio*
12:00-12:15	**[O7.6] A heterologous prime-boost vaccine regimen induces long-lasting neutralizing antibody response capable of preventing Ebola virus-like particle entry in mice.** Dapeng Li, *Inst. Pasteur*	**[O8.6] A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.** Lázaro Gil González, *Ctr. Genetic Engr. Biotech*	**[O9.7] Design and Characterization of a COBRA H1N1 HA Vaccine in a Pre-Immune Ferret Model**. Donald Carter, *U. Georgia*

12:15-12:30	**[O7.7] Perspectives of a tumor vaccine based on attenuated *Listeria monocytogenes* for prevention and treatment of hepatocellular carcinoma.** Tetyana Yevsa, MHH, *Hannover*	**[O8.7] Extreme Polyvalency Induces Potent Cross-Clade Cellular and Humoral Responses in Rabbits and Non-human Primates** Megan Wise, *UPenn, Wistar Institute*	**[O9.8] Efficacy of Adenovirus Vector-Based Multi-Epitope Vaccine against A/H5, A/H7, and A/H9 Avian Influenza Viruses.** Ahmed Hassan, *Purdue Univ.*
12:30-12:45	**[O7.8] Novel recombinant HIV vaccine candidates based on replication-defective flavivirus vectors demonstrate favorable safety and immunogenicity profile in NHP.** Maryann Giel-Moloney, *Sanofi-Pasteur*	**[O8.8] Vaccines against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) elicit humoral and cellular immune responses in mice** Naif Alharbi, *Univ. of Oxford, King Abdullah International Medical Research Center*	**[P80] Single-Cycle Adenoviruses (SC-Ads) as Antigen Gene Amplifying Vaccines** Michael Barry, *Mayo Clinic*
12:45-13:45	**Lunch *(Harbor View Ballroom and Commonwealth Ballroom)*** **Sponsored By Invoio Pharmaceuticals**		
13:00-13:45	**Career Development Panel: Laina King, NIH, Shan Lu, UMASS, Annie De Groot, URI/EpiVax, Nicola Lamonica, Johnson & Johnson Innovation** ***(Commonwealth Room)***		
13:45-14:00	**ISV Award Ceremony *(Grand Ballroom)***		
14:00-16:00	**Plenary Session Six: One Health and Emerging Diseases** **Session Chairs: David Weiner and Margaret Liu**		
14:00-14:30	**[PL6.1] Lessons Learned from Ebola R & D during a Health Emergency** Marie-Paule Kieny, *World Health Organization*		
14:30-15:00	**[PL6.2] Lessons Learned from Sanofi Pasteurs Dengue Vaccine Program and Challenges for Zika** Nick Jackson, *Sanofi Pasteur*		
15:00-15:15	**[PL6.3] Contact and Distance Transmission of Ebola Virus in Non-Human Primates** Gary Kobinger, *Université Laval*		
15:15-15:30	**[PL6.4] Rabies Vector for Ebola; NHP studies**. Drishya Kurup, *Thomas Jefferson Univ.*		
15:30-15:45	**[PL6.5] Clinical Assessment of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Caused by Hantivirus Infections.** Connie Schmaljohn, *USAMRIID*		
15:45-16:00	**[PL6.6] Discovery of Toxoplasma Gondii Vaccine Candiate Antigens.** Mert Doskaya, *Ege Univ.*		
16:00-16:15	**Closing Remarks and Introduction of 2017 ISV Annual Congress *(Grand Ballroom)***		